About Timothy Siegert
Timothy Siegert is chief operating officer and co-founder of Allyx Therapeutics, which develops oral medicines for Alzheimer’s disease and Parkinson’s disease. In 2024, he was principal investigator for an NIH Allyx study of how an experimental Alzheimer’s drug is processed by the body.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Timothy Siegert in the role, so the role may have started earlier or lasted longer.
Allyx Therapeutics, Inc. Current
COO & Co-Founder
Principal Investigator (2024 – 2026)
2021 – Present · New Haven, CT
A clinical-stage drug developer building oral treatments to protect brain-cell connections from neurodegenerative disease.
Key Colleagues at Startups
The people Timothy Siegert works with at each company, as listed on that company's latest Form D.
Allyx Therapeutics, Inc. · Form D/A, Oct 21, 2026
SB
Stephen Bloch
CEO & Co-Founder, director
SS
Stephen Strittmatter
Scientific Founder and director
Paul Fonteyne
Co-Founder and director
GH
Gregory Ho
Director
RB
Robert Bettigole
Director
Kevin Rakin
Director